Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 296

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 296
---
 delay or termination. The results
of clinical trials are open to differing interpretations.

Any
failure by us to comply with existing regulations could harm our reputation and operating results.

The
regulatory approval processes with the FDA are lengthy and inherently unpredictable.

There
is a high rate of failure for drug candidates proceeding through clinical trials.

Risks
Related to Our Reliance Upon Third Parties

We
rely on, and expect to continue to rely on, third parties to conduct clinical trials for our product candidates.

Our
existing collaboration arrangements and any that we may enter into in the future may not be successful, which could adversely affect
our ability to develop and commercialize our product candidates.

Risks
Relating to the Ownership of Our Common Stock

Because
of the speculative nature of an investment in our company, you may lose your entire investment.

Certain
of our founding stockholders, plus our existing officers and directors, control a substantial interest in us and thus may influence certain
actions requiring stockholder vote.

Risks
Related to Our Intellectual Property

We
depend on rights to Telomir-1 that are or will be licensed to us. We do not own the intellectual property rights to Telomir-1 and any
loss of our rights to it could prevent us from selling our product.

Within
our present and future pipeline of treatments, Telomir-1 is in-licensed from another company. We do not currently own any intellectual
property rights, including the patent application that underlies this license. Our rights to use Telomir-1 is subject to the negotiation
of, continuation of and compliance with the terms of this license. Thus, the non-provisional patent application is not written by us
or our attorneys, and we did not have control over the drafting and prosecution. The patent owner and our licensor might not have given
the same attention to the drafting and prosecution of these patents and applications as we would have if we had been the owner of the
patent application and had control over the drafting. We cannot be certain that drafting of the licensed patent application, or patent
prosecution, by the licensor have been or will be conducted in compliance with applicable laws and regulations or will result in valid
and enforceable patents and other intellectual property rights. This absence of control over the drafting, prosecution of patent and
applications, along with non-compliance with royalty payments and confidentiality breaches are just some of the ways that may result
in the Company’s’ loss of the license